Crizotinib
CAS 877399-52-5
Crizotinib (CAS 877399-52-5) is a pharmaceutical compound with 80 bioactivity targets and 674 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
158
SOURCE
DrugCentral
Adverse signals
674
SOURCE
IUPHAR/BPS
PubMed IDs
3
SOURCE
DrugCentral
055904D152D6
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Crizotinib
CAS Number
877399-52-5
UNII
53AH36668S
InChIKey
KTEIFNKAUNYNJU-GFCCVEGCSA-N
ChEMBL ID
CHEMBL601719
DrugCentral Struct ID
4187
Source Match
DrugCentral (CAS), FDA GSRS (UNII)
Synonyms and normalized names
Xalkori
SOURCE
EMBL-EBI ChEMBL
80 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| Tyrosine-protein kinase JAK3 Kinase |
Kd | 6.7 | - | Homo sapiens |
| Macrophage-stimulating protein receptor Kinase |
Kd | 7.6 | - | Homo sapiens |
| Tyrosine-protein kinase ABL1 Kinase |
Kd | 8 | - | Homo sapiens |
| Mast/stem cell growth factor receptor Kit Kinase |
Kd | 6.1 | - | Homo sapiens |
| Epidermal growth factor receptor Kinase |
Kd | 5.57 | - | Homo sapiens |
| Breakpoint cluster region protein Kinase |
Kd | 5.61 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase Src Kinase |
Kd | 6.25 | - | Homo sapiens |
| Tyrosine-protein kinase Lck Kinase |
Kd | 7.52 | - | Homo sapiens |
| Tyrosine-protein kinase Yes Kinase |
Kd | 6.11 | - | Homo sapiens |
| Tyrosine-protein kinase Fyn Kinase |
Kd | 5.89 | - | Homo sapiens |
| Ephrin type-A receptor 2 Kinase |
Kd | 7 | - | Homo sapiens |
| Receptor-type tyrosine-protein kinase FLT3 Kinase |
Kd | 6.68 | - | Homo sapiens |
| Proto-oncogene tyrosine-protein kinase receptor Ret Kinase |
Kd | 5.89 | - | Homo sapiens |
| Vascular endothelial growth factor receptor 1 Kinase |
Kd | 5.64 | - | Homo sapiens |
| Macrophage colony-stimulating factor 1 receptor Kinase |
Kd | 6.68 | - | Homo sapiens |
| Insulin-like growth factor 1 receptor Kinase |
Kd | 6.11 | - | Homo sapiens |
| Insulin receptor Kinase |
Kd | 6.47 | - | Homo sapiens |
| Fibroblast growth factor receptor 3 Kinase |
Kd | 5.57 | - | Homo sapiens |
| Rho-associated protein kinase 1 Kinase |
Kd | 5.43 | - | Homo sapiens |
| Focal adhesion kinase 1 Kinase |
Kd | 6.51 | - | Homo sapiens |
| Tyrosine-protein kinase JAK1 Kinase |
Kd | 6.48 | - | Homo sapiens |
| High affinity nerve growth factor receptor Kinase |
Kd | 7.02 | - | Homo sapiens |
| Tyrosine-protein kinase JAK2 Kinase |
Kd | 6.54 | - | Homo sapiens |
| Rho-associated protein kinase 2 Kinase |
Kd | 5.48 | - | Homo sapiens |
| Tyrosine-protein kinase SYK Kinase |
Kd | 5.6 | - | Homo sapiens |
| Angiopoietin-1 receptor Kinase |
Kd | 6.57 | - | Homo sapiens |
| Ephrin type-A receptor 8 Kinase |
Kd | 6.55 | - | Homo sapiens |
| AP2-associated protein kinase 1 Kinase |
Kd | 5.64 | - | Homo sapiens |
| Hepatocyte growth factor receptor Kinase |
Kd | 9.26 | - | Homo sapiens |
| Tyrosine-protein kinase Lyn Kinase |
Kd | 6.03 | - | Homo sapiens |
| Cytoplasmic tyrosine-protein kinase BMX Kinase |
Kd | 5.44 | - | Homo sapiens |
| LIM domain kinase 1 Kinase |
Kd | 6.08 | - | Homo sapiens |
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase |
Kd | 5.62 | - | Homo sapiens |
| Serine/threonine-protein kinase 10 Kinase |
Kd | 7.36 | - | Homo sapiens |
| Tyrosine-protein kinase Fer Kinase |
Kd | 6.57 | - | Homo sapiens |
| Serine/threonine-protein kinase PLK4 Kinase |
Kd | 7.22 | - | Homo sapiens |
| Aurora kinase C Kinase |
Kd | 5.37 | - | Homo sapiens |
| Abelson tyrosine-protein kinase 2 Kinase |
Kd | 6.34 | - | Homo sapiens |
| Ephrin type-A receptor 5 Kinase |
Kd | 6 | - | Homo sapiens |
| Ephrin type-A receptor 4 Kinase |
Kd | 6.44 | - | Homo sapiens |
| Ephrin type-A receptor 6 Kinase |
Kd | 7.19 | - | Homo sapiens |
| Tyrosine-protein kinase Fgr Kinase |
Kd | 6.17 | - | Homo sapiens |
| Aurora kinase A Kinase |
Kd | 6.59 | - | Homo sapiens |
| ALK tyrosine kinase receptor Kinase |
Ki | 9.13 | - | Homo sapiens |
| Ephrin type-A receptor 3 Kinase |
Kd | 6.15 | - | Homo sapiens |
| BMP-2-inducible protein kinase Kinase |
Kd | 6.13 | - | Homo sapiens |
| Tyrosine-protein kinase FRK Kinase |
Kd | 5.54 | - | Homo sapiens |
| Mitogen-activated protein kinase kinase kinase kinase 5 Kinase |
Kd | 7.1 | - | Homo sapiens |
| Receptor-interacting serine/threonine-protein kinase 2 Kinase |
Kd | 6.05 | - | Homo sapiens |
| Ephrin type-B receptor 1 Kinase |
Kd | 6.92 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Neoplasm progression | 637 | 1922.725 | 10061309 |
| Disease progression | 897 | 1779.242 | 10061818 |
| Death | 1078 | 1167.979 | 10011906 |
| Visual impairment | 261 | 389.572 | 10047571 |
| Nausea | 710 | 311.828 | 10028813 |
| Photopsia | 92 | 301.821 | 10034962 |
| Oedema peripheral | 275 | 205.486 | 10030124 |
| Vomiting | 458 | 184.32 | 10047700 |
| Pleural effusion | 191 | 174.929 | 10035598 |
| Dysgeusia | 126 | 163.352 | 10013911 |
| Diarrhoea | 516 | 147.353 | 10012735 |
| Renal abscess | 36 | 144.909 | 10038351 |
| Oesophagitis | 81 | 140.323 | 10030216 |
| Constipation | 251 | 135.295 | 10010774 |
| Interstitial lung disease | 146 | 134.447 | 10022611 |
| Pneumonitis | 111 | 133.716 | 10035742 |
| Drug resistance | 95 | 120.269 | 10059866 |
| Oedema | 144 | 117.827 | 10030095 |
| Vitreous floaters | 50 | 114.838 | 10047654 |
| Metastases to central nervous system | 64 | 112.519 | 10059282 |
| Acquired gene mutation | 32 | 101.504 | 10069754 |
| Dysphagia | 129 | 90.248 | 10013950 |
| Transaminases increased | 77 | 78.813 | 10054889 |
| Decreased appetite | 218 | 75.933 | 10061428 |
| Pulmonary embolism | 140 | 74.185 | 10037377 |
| Renal impairment | 131 | 72.455 | 10062237 |
| Second primary malignancy | 44 | 68.688 | 10039801 |
| Malignant neoplasm progression | 121 | 68.188 | 10051398 |
| Drug ineffective | 130 | 66.235 | 10013709 |
| Pericardial effusion | 66 | 64.896 | 10034474 |
| Embolism | 40 | 60.175 | 10061169 |
| Vision blurred | 102 | 59.063 | 10047513 |
| Hypoalbuminaemia | 44 | 57.505 | 10020942 |
| Hepatic function abnormal | 75 | 56.689 | 10019670 |
| Renal cyst | 39 | 54.757 | 10038423 |
| Electrocardiogram QT prolonged | 83 | 54.417 | 10014387 |
| Oesophageal ulcer | 28 | 53.586 | 10030201 |
| Drug hypersensitivity | 9 | 51.765 | 10013700 |
| Alanine aminotransferase increased | 113 | 51.048 | 10001551 |
| Hepatotoxicity | 63 | 50.372 | 10019851 |
| Renal cyst infection | 11 | 48.272 | 10058596 |
| Bradycardia | 97 | 48.181 | 10006093 |
| Arthralgia | 51 | 45.435 | 10003239 |
| Carcinoembryonic antigen increased | 17 | 43.112 | 10007266 |
| Aspartate aminotransferase increased | 95 | 42.316 | 10003481 |
| Rheumatoid arthritis | 6 | 41.491 | 10039073 |
| Pain | 83 | 38.732 | 10033371 |
| Sinus bradycardia | 36 | 37.701 | 10040741 |
| Oesophageal pain | 19 | 37.632 | 10030180 |
| Therapeutic product effect decreased | 3 | 36.665 | 10082201 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
3 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| ALK receptor tyrosine kinase ALK |
Inhibition | 9.0 pIC50 | 21812414 |
| MET proto-oncogene, receptor tyrosine kinase MET |
Inhibition | 8.699999809265137 pKi | 21812414 |
| MET proto-oncogene, receptor tyrosine kinase MET |
Inhibition | 9.100000381469727 pIC50 | 21708465 |
SOURCE
PharmGKB
3 phenotype rows
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
ABCB1 (PA267) rs1045642
Genotype AA is associated with increased exposure to crizotinib in people with.
Evidence: -; PMID 27270784
ABCB1 (PA267) rs1128503
Genotype AA is associated with increased exposure to crizotinib in people with.
Evidence: -; PMID 27270784
ABCB1 (PA267) rs2032582
Genotype AA is associated with increased exposure to crizotinib in people with.
Evidence: -; PMID 27270784
SOURCE
NLM RxNorm
3 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| CRIZOTINIB | 1148495 | SU | MTHSPL |
| crizotinib | 1148495 | IN | RXNORM |
| Xalkori | 1148499 | BN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abscess | crizotinib | LLT | C0000833 |
| Abscess | crizotinib | PT | C0000833 |
| Acute respiratory distress syndrome | crizotinib | LLT | C0035222 |
| Acute respiratory distress syndrome | crizotinib | PT | C0035222 |
| Alanine aminotransferase increased | crizotinib | LLT | C0151905 |
| Alanine aminotransferase increased | crizotinib | PT | C0151905 |
| Anaemia | crizotinib | LLT | C0002871 |
| Anaemia | crizotinib | PT | C0002871 |
| Arrhythmia | crizotinib | LLT | C0003811 |
| Arrhythmia | crizotinib | PT | C0003811 |
| Aspartate aminotransferase increased | crizotinib | LLT | C0151904 |
| Aspartate aminotransferase increased | crizotinib | PT | C0151904 |
| Asthenia | crizotinib | PT | C0004093 |
| Balance disorder | crizotinib | LLT | C0575090 |
| Balance disorder | crizotinib | PT | C0575090 |
| Blood alkaline phosphatase increased | crizotinib | PT | C0852911 |
| Blood alkaline phosphatase increased | crizotinib | LLT | C0852911 |
| Blood alkaline phosphatase increased | crizotinib | PT | C0852911 |
| Blood and lymphatic system disorders | crizotinib | - | C0851353 |
| Body temperature increased | crizotinib | LLT | C0015967 |
| Body temperature increased | crizotinib | PT | C0015967 |
| Bradycardia | crizotinib | LLT | C0428977 |
| Bradycardia | crizotinib | PT | C0428977 |
| Burning sensation | crizotinib | LLT | C0085624 |
| Burning sensation | crizotinib | PT | C0085624 |
| Cardiac disorder | crizotinib | LLT | C0018799 |
| Cardiac disorder | crizotinib | PT | C0018799 |
| Congenital renal cyst | crizotinib | LLT | C0268800 |
| Congenital renal cyst | crizotinib | PT | C0268800 |
| Constipation | crizotinib | LLT | C0009806 |
| Constipation | crizotinib | PT | C0009806 |
| Decreased appetite | crizotinib | LLT | C0232462 |
| Decreased appetite | crizotinib | PT | C0232462 |
| Dermatitis | crizotinib | PT | C0011603 |
| Diarrhoea | crizotinib | LLT | C0011991 |
| Diarrhoea | crizotinib | PT | C0011991 |
| Diplopia | crizotinib | LLT | C0012569 |
| Diplopia | crizotinib | PT | C0012569 |
| Disease progression | crizotinib | LLT | C0242656 |
| Disease progression | crizotinib | PT | C0242656 |
| Disorder sight | crizotinib | LLT | C0042790 |
| Dizziness | crizotinib | LLT | C0012833 |
| Dizziness | crizotinib | PT | C0012833 |
| Dizziness | crizotinib | PT | C0012833 |
| Dizziness postural | crizotinib | LLT | C0234987 |
| Dizziness postural | crizotinib | PT | C0234987 |
| Drug-induced liver injury | crizotinib | LLT | C0860207 |
| Drug-induced liver injury | crizotinib | PT | C0860207 |
| Dysaesthesia | crizotinib | LLT | C0392699 |
| Dysaesthesia | crizotinib | PT | C0392699 |
| Dysgeusia | crizotinib | LLT | C0013378 |
| Dysgeusia | crizotinib | PT | C0013378 |
| Dyspepsia | crizotinib | LLT | C0013395 |
| Dyspepsia | crizotinib | PT | C0013395 |
| Dyspnoea | crizotinib | LLT | C0013404 |
| Dyspnoea | crizotinib | PT | C0013404 |
| Electrocardiogram QT corrected interval prolonged | crizotinib | LLT | C0855333 |
| Electrocardiogram QT prolonged | crizotinib | LLT | C0151878 |
| Electrocardiogram QT prolonged | crizotinib | PT | C0151878 |
| Electrocardiogram QT prolonged | crizotinib | PT | C0151878 |
| Eye disorder | crizotinib | LLT | C0015397 |
| Eye disorder | crizotinib | PT | C0015397 |
| Face oedema | crizotinib | LLT | C0542571 |
| Face oedema | crizotinib | PT | C0542571 |
| Fatal outcomes | crizotinib | - | C0206277 |
| Fatigue | crizotinib | LLT | C0015672 |
| Fatigue | crizotinib | PT | C0015672 |
| Febrile neutropenia | crizotinib | LLT | C0746883 |
| Febrile neutropenia | crizotinib | PT | C0746883 |
| Fluid retention | crizotinib | PT | C0268000 |
| Gait disturbance | crizotinib | LLT | C0575081 |
| Gait disturbance | crizotinib | PT | C0575081 |
| Gamma-glutamyltransferase increased | crizotinib | LLT | C0151662 |
| Gamma-glutamyltransferase increased | crizotinib | PT | C0151662 |
| Gastrointestinal disorder | crizotinib | LLT | C0017178 |
| Gastrointestinal disorder | crizotinib | PT | C0017178 |
| Gastrointestinal perforation | crizotinib | LLT | C0151664 |
| Gastrointestinal perforation | crizotinib | PT | C0151664 |
| Generalised oedema | crizotinib | LLT | C0151603 |
| Generalised oedema | crizotinib | PT | C0151603 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Crizotinib used for in pharmaceutical contexts?
Crizotinib (CAS 877399-52-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Crizotinib?
Crizotinib has 674 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Neoplasm progression, Disease progression, Death, Visual impairment, Nausea. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Crizotinib also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Crizotinib.
What clinical phase is Crizotinib in?
No phase 1-4 clinical development badge is rendered for Crizotinib because the matched compound identifier rows do not contain a max-phase value.
What bioactivity targets are documented for Crizotinib?
Crizotinib has 158 bioactivity rows in this page query. Rendered target entries include Tyrosine-protein kinase JAK3, Macrophage-stimulating protein receptor, Tyrosine-protein kinase ABL1, Mast/stem cell growth factor receptor Kit, Epidermal growth factor receptor.